AACR Project GENIE: Powering Precision Medicine through an International Consortium
AACR Project GENIE Consortium, Fabrice André, Monica Arnedos, Alexander S Baras, José Baselga, Philippe L Bedard, Michael F Berger, Mariska Bierkens, Fabien Calvo, Ethan Cerami, Debyani Chakravarty, Kristen K Dang, Nancy E Davidson, Catherine Del Vecchio Fitz, Semih Dogan, Raymond N DuBois, Matthew D Ducar, P Andrew Futreal, Jianjiong Gao, Francisco Garcia, Stu Gardos, Christopher D Gocke, Benjamin E Gross, Justin Guinney, Zachary J Heins, Stephanie Hintzen, Hugo Horlings, Jan Hudeček, David M Hyman, Suzanne Kamel-Reid, Cyriac Kandoth, Walter Kinyua, Priti Kumari, Ritika Kundra, Marc Ladanyi, Céline Lefebvre, Michele L LeNoue-Newton, Eva M Lepisto, Mia A Levy, Neal I Lindeman, James Lindsay, David Liu, Zhibin Lu, Laura E MacConaill, Ian Maurer, David S Maxwell, Gerrit A Meijer, Funda Meric-Bernstam, Christine M Micheel, Clinton Miller, Gordon Mills, Nathanael D Moore, Petra M Nederlof, Larsson Omberg, John A Orechia, Ben Ho Park, Trevor J Pugh, Brendan Reardon, Barrett J Rollins, Mark J Routbort, Charles L Sawyers, Deborah Schrag, Nikolaus Schultz, Kenna R Mills Shaw, Priyanka Shivdasani, Lillian L Siu, David B Solit, Gabe S Sonke, Jean Charles Soria, Parin Sripakdeevong, Natalie H Stickle, Thomas P Stricker, Shawn M Sweeney, Barry S Taylor, Jelle J Ten Hoeve, Stacy B Thomas, Eliezer M Van Allen, Laura J Van 't Veer, Tony van de Velde, Harm van Tinteren, Victor E Velculescu, Carl Virtanen, Emile E Voest, Lucy L Wang, Chetna Wathoo, Stuart Watt, Celeste Yu, Thomas V Yu, Emily Yu, Ahmet Zehir, Hongxin Zhang, AACR Project GENIE Consortium, Fabrice André, Monica Arnedos, Alexander S Baras, José Baselga, Philippe L Bedard, Michael F Berger, Mariska Bierkens, Fabien Calvo, Ethan Cerami, Debyani Chakravarty, Kristen K Dang, Nancy E Davidson, Catherine Del Vecchio Fitz, Semih Dogan, Raymond N DuBois, Matthew D Ducar, P Andrew Futreal, Jianjiong Gao, Francisco Garcia, Stu Gardos, Christopher D Gocke, Benjamin E Gross, Justin Guinney, Zachary J Heins, Stephanie Hintzen, Hugo Horlings, Jan Hudeček, David M Hyman, Suzanne Kamel-Reid, Cyriac Kandoth, Walter Kinyua, Priti Kumari, Ritika Kundra, Marc Ladanyi, Céline Lefebvre, Michele L LeNoue-Newton, Eva M Lepisto, Mia A Levy, Neal I Lindeman, James Lindsay, David Liu, Zhibin Lu, Laura E MacConaill, Ian Maurer, David S Maxwell, Gerrit A Meijer, Funda Meric-Bernstam, Christine M Micheel, Clinton Miller, Gordon Mills, Nathanael D Moore, Petra M Nederlof, Larsson Omberg, John A Orechia, Ben Ho Park, Trevor J Pugh, Brendan Reardon, Barrett J Rollins, Mark J Routbort, Charles L Sawyers, Deborah Schrag, Nikolaus Schultz, Kenna R Mills Shaw, Priyanka Shivdasani, Lillian L Siu, David B Solit, Gabe S Sonke, Jean Charles Soria, Parin Sripakdeevong, Natalie H Stickle, Thomas P Stricker, Shawn M Sweeney, Barry S Taylor, Jelle J Ten Hoeve, Stacy B Thomas, Eliezer M Van Allen, Laura J Van 't Veer, Tony van de Velde, Harm van Tinteren, Victor E Velculescu, Carl Virtanen, Emile E Voest, Lucy L Wang, Chetna Wathoo, Stuart Watt, Celeste Yu, Thomas V Yu, Emily Yu, Ahmet Zehir, Hongxin Zhang
Abstract
The AACR Project GENIE is an international data-sharing consortium focused on generating an evidence base for precision cancer medicine by integrating clinical-grade cancer genomic data with clinical outcome data for tens of thousands of cancer patients treated at multiple institutions worldwide. In conjunction with the first public data release from approximately 19,000 samples, we describe the goals, structure, and data standards of the consortium and report conclusions from high-level analysis of the initial phase of genomic data. We also provide examples of the clinical utility of GENIE data, such as an estimate of clinical actionability across multiple cancer types (>30%) and prediction of accrual rates to the NCI-MATCH trial that accurately reflect recently reported actual match rates. The GENIE database is expected to grow to >100,000 samples within 5 years and should serve as a powerful tool for precision cancer medicine.Significance: The AACR Project GENIE aims to catalyze sharing of integrated genomic and clinical datasets across multiple institutions worldwide, and thereby enable precision cancer medicine research, including the identification of novel therapeutic targets, design of biomarker-driven clinical trials, and identification of genomic determinants of response to therapy. Cancer Discov; 7(8); 818-31. ©2017 AACR.See related commentary by Litchfield et al., p. 796This article is highlighted in the In This Issue feature, p. 783.
Conflict of interest statement
Disclosure of Potential Conficts of Interest: F. André reports receiving commercial research grants from Astra-Zeneca, Lilly, Novartis, and Pfzer. M. Arnedos has received honoraria from the speakers bureaus of Novartis and AstraZeneca, and is a consultant/advisory board member for Puma. D.M. Hyman reports receiving commercial research grants from AstraZeneca, Loxo Oncology, and PUMA Biotechnology, and is a consultant/advisory board member for Atara Biotherapeutics, Chugai, and CytomX. M.A. Levy is an advisory board member of Personalis, Inc., and receives royalty distribution from GenomOncology. F. Meric-Bernstam reports receiving commercial research grants from Aileron, AstraZeneca, Bayer, Calithera, Curis, CytoMx, Debiopharma, Effective Pharma, Genentech, Jounce, Novartis, PUMA, Taiho, and Zymeworks, and is a consultant/advisory board member for Clearlight Diagnostics, Darwin Health, Dialecta, GRAIL, Infection Biosciences, and Pieris. G.B. Mills reports receiving commercial research grants from Adelson Medical Research Foundation, AstraZeneca, Breast Cancer Research Foundation, Critical Outcome Technologies, Illumina, Karus, Komen Research Foundation, NanoString, and Takeda/Millennium Pharmaceuticals; has received honoraria from the speakers bureaus of Allostery, AstraZeneca, ImmunoMet, ISIS Pharmaceuticals, Lilly, MedImmune, Novartis, Pfzer, Symphogen, and Tarveda; has ownership interest (including patents) in Catena Pharmaceuticals, ImmunoMet, Myriad Genetics, PTV Ventures, and Spindletop Ventures; and is a consultant/advisory board member for Adventist Health, Allostery, AstraZeneca, Catena Pharmaceuticals, Critical Outcome Technologies, ImmunoMet, ISIS Pharmaceuticals, Lilly, MedImmune, Novartis, Precision Medicine, Provista Diagnostics, Signalchem Lifesciences, Symphogen, Takeda/Millennium Pharmaceuticals, Tarveda, and Tau Therapeutics. T.J. Pugh is a consultant/advisory board member for Dynacare. C.L. Sawyers is a consultant/advisory board member for Novartis. V.E. Velculescu has ownership interest (including patents) in Personal Genome Diagnostics and is a consultant/advisory board member for the same. No potential conflicts of interest were disclosed by the other authors.\One of the Editors-in-Chief is an author on this article. In keeping with the AACR's editorial policy, the peer review of this submission was managed by a senior member of Cancer Discovery's editorial team; a member of the AACR Publications Committee rendered the final decision concerning acceptability.
©2017 American Association for Cancer Research.
Figures
Source: PubMed